Trojansk häst-metod i läkemedel mot fetma ökar viktnedgången hos möss

8 maj 2026

Rapporterad av AI

Forskare har utvecklat en hybridbehandling mot fetma som använder GLP-1- och GIP-signaler för att leverera en metabolisk förstärkare direkt in i cellerna. Tidiga tester på möss visade större viktnedgång och bättre blodsockerkontroll än standardbehandlingar. Metoden syftar till att minska biverkningar genom att begränsa läkemedlets verkan till specifika målområden.

Forskare vid Helmholtz Munich skapade föreningen genom att koppla samman en inkretinbaserad molekyl med lanifibranor, en pan-PPAR-agonist. Designen fungerar som en trojansk häst, vilket gör att det extra läkemedlet kan ta sig in i cellerna via GLP-1- eller GIP-receptorer innan det aktiverar brytare som reglerar fett- och sockeromsättningen inne i cellkärnan.

Relaterade artiklar

Medical team discussing integrated obesity care with GLP-1 drugs, endoscopy, surgery and precision medicine.

Updated POWER framework urges multidisciplinary obesity care beyond GLP-1 drugs

20 juni 2026 Rapporterad av AI Bild genererad av AI Faktagranskad

A new Gastroenterology commentary revisits the American Gastroenterological Association’s 2017 POWER framework, arguing that GLP-1 medicines should be integrated with endoscopic therapies, bariatric surgery and precision medicine to improve long-term obesity outcomes.

Oral GLP-1 pill shows strong results in diabetes trial

A new experimental oral medication called elecoglipron improved blood sugar control and promoted weight loss in adults with type 2 diabetes during a phase 2b trial. Results from the SOLSTICE study were presented at the American Diabetes Association's Scientific Sessions and published in The Lancet.

Japanese study links GLP-1 response to ‘external eating’ habits in people with type 2 diabetes

8 maj 2026 Rapporterad av AI Faktagranskad

A year-long observational study in Japan suggests that people with type 2 diabetes who tend to overeat in response to tempting food cues such as sight and smell may see greater weight loss—and possibly better blood-sugar improvement—after starting GLP-1 receptor agonists, while those with primarily emotional eating patterns show less consistent links to long-term outcomes.

Health

Study links Ozempic to lower depression and anxiety risks

Asia

Young Indians risk health with Ozempic, Mounjaro for pre-wedding weight loss

Health

FDA approves Eli Lilly’s once-daily obesity pill Foundayo

Study finds GLP-1 hormone at very low levels in arthritic joint fluid

Researchers at Aarhus University report that the hormone GLP-1—mimicked by drugs such as Wegovy—can be measured in the joint fluid of patients with inflammatory arthritis, but only at very low levels. The findings, published in The Lancet Rheumatology, suggest GLP-1–based medicines might eventually be studied for potential direct effects on joint inflammation, though the researchers say clinical trials are needed to show whether such treatment works.

Study links PAM gene variants to weaker blood-sugar response to GLP-1 drugs such as Ozempic

5 juni 2026 Rapporterad av AI Faktagranskad

Researchers say genetic variants in the PAM gene may help explain why some people with Type 2 diabetes get less blood-sugar benefit from GLP-1 receptor agonist drugs such as Ozempic, a phenomenon they describe as “GLP-1 resistance.”

14 juni 2026 20:53